Evidence method
Level · gp.fundamentals.debt_to_revenue
3118.84% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TCRX · Jun 30, 2026
TScan Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-345749General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
46.91% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-2619.89% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-65.83% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-2901.33% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2226.64% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
224.26% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 3325.25%
- Current
- 3118.84%
- Delta
- -206.42%
- Previous
- 7.13%
- Current
- 46.91%
- Delta
- 39.78%
- Previous
- -2472.40%
- Current
- -2619.89%
- Delta
- -147.48%
- Previous
- -54.77%
- Current
- -65.83%
- Delta
- -11.06%
- Previous
- -2967.31%
- Current
- -2901.33%
- Delta
- 65.98%
- Previous
- 2230.55%
- Current
- 2226.64%
- Delta
- -3.91%
- Previous
- 251.02%
- Current
- 224.26%
- Delta
- -26.76%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Biological Products, (No Diagnostic Substances) peers →Has State · TScan Therapeutics, Inc. →Transitioned To · TCRX Fundamental State →Transitioned To · TCRX BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TCRX CAPEX_INTENSITY_INCREASED →Transitioned To · TCRX CASH_GENERATION_DECREASED →Transitioned To · TCRX GROWTH_DECREASED →Transitioned To · TCRX PROFITABILITY_INCREASED →Transitioned To · TCRX R_AND_D_INTENSITY_DECREASED →Transitioned To · TCRX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.